PRESS RELEASE published on 06/29/2026 at 22:05, 1 month 2 days ago Abivax Reports Positive ABTECT Maintenance Part 2 Results for Obefazimod, Demonstrating Meaningful Clinical Benefit in Refractory UC Patients and Strengthening the Phase 3 Maintenance Safety Database Abivax reports positive ABTECT Maintenance Part 2 results for obefazimod in refractory UC patients, demonstrating meaningful clinical benefit and strengthening safety database Abivax Obefazimod Clinical Benefit UC Patients Safety Database
BRIEF published on 06/17/2026 at 18:05, 1 month 14 days ago ABIVAX: Distribution of Shares and Voting Rights as of May 31, 2026 Voting Rights Shares Euronext AMF Abivax
BRIEF published on 06/02/2026 at 10:16, 2 months ago Bank of America Corporation exceeds 5% of ABIVAX's capital Actions Abivax Financial Market Crossing Thresholds Bank Of America
BRIEF published on 06/01/2026 at 22:10, 2 months ago Promising results of obefazimod in the treatment of ulcerative colitis Abivax Obefazimod Ulcerative Colitis Clinical Trial FDA Authorization
BRIEF published on 06/01/2026 at 22:10, 2 months ago Abivax Announces Phase 3 Trial Results for Ulcerative Colitis Treatment Abivax Obefazimod Ulcerative Colitis Clinical Trial Phase 3 Results
PRESS RELEASE published on 06/01/2026 at 22:05, 2 months ago Abivax Announces Landmark Phase 3 ABTECT Maintenance Trial Results Evaluating Obefazimod in Moderately to Severely Active Ulcerative Colitis Abivax announces positive Phase 3 ABTECT maintenance trial results for obefazimod in ulcerative colitis, demonstrating significant efficacy and safety profile. Plans NDA submission to FDA in late 2026 FDA Abivax Obefazimod Ulcerative Colitis Phase 3
BRIEF published on 05/29/2026 at 18:05, 2 months 3 days ago ABIVAX: Update on capital and voting rights Share Capital Voting Rights Actions AMF Abivax
BRIEF published on 05/29/2026 at 18:05, 2 months 3 days ago ABIVAX: Share Capital and Voting Rights as of April 30, 2026 Euronext Paris Share Capital Voting Rights AMF Abivax
BRIEF published on 05/22/2026 at 22:10, 2 months 10 days ago Abivax Reports Q1 2026 Financials and Key Developments in Obefazimod Trials Financial Results Abivax Obefazimod Ulcerative Colitis Clinical Trials
BRIEF published on 05/22/2026 at 22:10, 2 months 10 days ago Abivax unveils its Q1 2026 results and progress on Study 108 Financial Results Treasury Obefazimod RCH Study 108
Published on 08/01/2026 at 01:20, 1 day 9 hours ago Gamma Resources Announces $880,000 Private Placement with Full Warrant Coverage
Published on 08/01/2026 at 01:15, 1 day 9 hours ago Clean Air Metals and Fiore-Backed Springbok Ventures Announce Strategic Business Combination
Published on 08/01/2026 at 00:30, 1 day 10 hours ago Battery X Metals Announces Amendment to Corporate Awareness Engagement
Published on 07/31/2026 at 23:20, 1 day 11 hours ago Pentagon I Capital Corp. Announces Conditional Acceptance of Qualifying Transaction with Prospectiva Resources Ltd.
Published on 08/02/2026 at 08:15, 2 hours 42 minutes ago Holcim signs agreement to divest its business in the Philippines
Published on 08/01/2026 at 16:35, 18 hours 22 minutes ago HIZENERGY Enters Global Top Tier with BloombergNEF Tier 1 Listing
Published on 07/31/2026 at 19:55, 1 day 15 hours ago EQS-Adhoc: ABO Energy GmbH & Co. KGaA Reaches Agreement with Financing Partners on Extension of Standstill Agreement and Continuation of Restructuring Process
Published on 07/31/2026 at 19:05, 1 day 15 hours ago Eurobattery Minerals presents the Q2 report for 2026 as the Company accelerates the development of the San Juan tungsten project
Published on 07/31/2026 at 21:00, 1 day 13 hours ago Carrefour completes the sale of its minority stake in CarrefourSA in Turkey to Yeni Mağazacılık A.Ş., operator of the A101 retail chain and controlled by the Aydın Group
Published on 07/31/2026 at 19:13, 1 day 15 hours ago Covivio - Information on Treasury shares transactions between July 29th, 2026 and July 31st, 2026
Published on 07/31/2026 at 18:30, 1 day 16 hours ago Covivio Hotels - 2026 Half-year financial report